Literature DB >> 14632785

Chemical sensitization and regulation of TRAIL-induced apoptosis in a panel of B-lymphocytic leukaemia cell lines.

Jian Kang1, Rodrick R Kisenge, Hidemi Toyoda, Shigeki Tanaka, Jun Bu, Eiichi Azuma, Yoshihiro Komada.   

Abstract

Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) effectively kills tumour cells but not normal cells. We investigated TRAIL sensitivity and the TRAIL-induced apoptosis signalling pathway in a panel of B-lymphocytic leukaemia cell lines. Depending upon TRAIL sensitivity, leukaemia cells could be divided into three groups: highly sensitive, moderately sensitive and resistant. TRAIL receptor-2 (DR5) plays an important role in transducing apoptosis signals. DR5 was internalized into the cytoplasm where it recruited FAS-associated death domain protein (FADD) under TRAIL stimulation in both sensitive and resistant cells. However, the active form of caspase-8 was recruited to FADD and only sensitive cells showed increased caspase-8 activity upon TRAIL stimulation. The caspase-8 specific inhibitor, Z-IETD, impaired caspase-8 activation and completely abrogated TRAIL-induced apoptosis. These results suggest that TRAIL resistance in B-lymphocytic leukaemia cells is due to negative regulation at the level of caspase-8 activation and that caspase-8 activation is an indispensable process in TRAIL-induced apoptosis. However, FADD-like interleukin-1 beta-converting enzyme inhibitory protein (c-FLIPL) was similarly expressed and down-regulated after TRAIL stimulation in both sensitive and resistant cells. Interestingly, in some cell lines, TRAIL sensitivity and caspase-8 activity was enhanced or restored with the treatment of cycloheximide (CHX). In addition, X-linked inhibitor of apoptosis (XIAP) levels decreased significantly and rapidly following treatment with CHX. Down-regulation of XIAP may be responsible for enhancement or restoration of TRAIL sensitivity after CHX treatment in B-lymphocytic leukaemia cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14632785     DOI: 10.1046/j.1365-2141.2003.04699.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  12 in total

1.  Copy number abnormality of acute lymphoblastic leukemia cell lines based on their genetic subtypes.

Authors:  Chihiro Tomoyasu; Toshihiko Imamura; Toshihiro Tomii; Mio Yano; Daisuke Asai; Hiroaki Goto; Akira Shimada; Masashi Sanada; Shotaro Iwamoto; Junko Takita; Masayoshi Minegishi; Takeshi Inukai; Kanji Sugita; Hajime Hosoi
Journal:  Int J Hematol       Date:  2018-05-21       Impact factor: 2.490

2.  Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma.

Authors:  Tamer E Fandy; Sharmila Shankar; Douglas D Ross; Edward Sausville; Rakesh K Srivastava
Journal:  Neoplasia       Date:  2005-07       Impact factor: 5.715

3.  Modulating cell-to-cell variability and sensitivity to death ligands by co-drugging.

Authors:  Deborah A Flusberg; Peter K Sorger
Journal:  Phys Biol       Date:  2013-06-04       Impact factor: 2.583

4.  SMG1 and NIK regulate apoptosis induced by Smac mimetic compounds.

Authors:  H H Cheung; M St Jean; S T Beug; R Lejmi-Mrad; E LaCasse; S D Baird; D F Stojdl; R A Screaton; R G Korneluk
Journal:  Cell Death Dis       Date:  2011-04-14       Impact factor: 8.469

5.  Selenocysteine derivative overcomes TRAIL resistance in melanoma cells: evidence for ROS-dependent synergism and signaling crosstalk.

Authors:  Wenqiang Cao; Xiaoling Li; Shanyuan Zheng; Wenjie Zheng; Yum-Shing Wong; Tianfeng Chen
Journal:  Oncotarget       Date:  2014-09-15

6.  Anti-leukemic activity of bortezomib and carfilzomib on B-cell precursor ALL cell lines.

Authors:  Kazuya Takahashi; Takeshi Inukai; Toshihiko Imamura; Mio Yano; Chihiro Tomoyasu; David M Lucas; Atsushi Nemoto; Hiroki Sato; Meixian Huang; Masako Abe; Keiko Kagami; Tamao Shinohara; Atsushi Watanabe; Shinpei Somazu; Hiroko Oshiro; Koshi Akahane; Kumiko Goi; Jiro Kikuchi; Yusuke Furukawa; Hiroaki Goto; Masayoshi Minegishi; Shotaro Iwamoto; Kanji Sugita
Journal:  PLoS One       Date:  2017-12-13       Impact factor: 3.240

7.  PED is overexpressed and mediates TRAIL resistance in human non-small cell lung cancer.

Authors:  Ciro Zanca; Michela Garofalo; Cristina Quintavalle; Giulia Romano; Mario Acunzo; Pia Ragno; Nunzia Montuori; Mariarosaria Incoronato; Luigi Tornillo; Daniel Baumhoer; Carlo Briguori; Luigi Terracciano; Gerolama Condorelli
Journal:  J Cell Mol Med       Date:  2008-02-15       Impact factor: 5.310

8.  Discovery and characterization of Isofistularin-3, a marine brominated alkaloid, as a new DNA demethylating agent inducing cell cycle arrest and sensitization to TRAIL in cancer cells.

Authors:  Cristina Florean; Michael Schnekenburger; Jin-Young Lee; Kyung Rok Kim; Aloran Mazumder; Sungmi Song; Jae-Myun Kim; Cindy Grandjenette; Jeoung-Gyun Kim; Ah-Young Yoon; Mario Dicato; Kyu-Won Kim; Christo Christov; Byung-Woo Han; Peter Proksch; Marc Diederich
Journal:  Oncotarget       Date:  2016-04-26

9.  Clofarabine exerts antileukemic activity against cytarabine-resistant B-cell precursor acute lymphoblastic leukemia with low deoxycytidine kinase expression.

Authors:  Meixian Huang; Takeshi Inukai; Kunio Miyake; Yoichi Tanaka; Keiko Kagami; Masako Abe; Hiroaki Goto; Masayoshi Minegishi; Shotaro Iwamoto; Eiji Sugihara; Atsushi Watanabe; Shinpei Somazu; Tamao Shinohara; Hiroko Oshiro; Koshi Akahane; Kumiko Goi; Kanji Sugita
Journal:  Cancer Med       Date:  2018-02-23       Impact factor: 4.452

10.  A20 Restricts Inflammatory Response and Desensitizes Gingival Keratinocytes to Apoptosis.

Authors:  Yajie Li; Erin C Mooney; Xia-Juan Xia; Nitika Gupta; Sinem Esra Sahingur
Journal:  Front Immunol       Date:  2020-03-10       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.